Back to top
more

CelSci (CVM)

(Delayed Data from AMEX)

$1.45 USD

1.45
82,052

-0.01 (-0.69%)

Updated Apr 25, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Cel-Sci Corporation [CVM]

Reports for Purchase

Showing records 21 - 29 ( 29 total )

Company: Cel-Sci Corporation

Industry: Medical - Biomedical and Genetics

Record: 21

03/02/2015

Company Report

Pages: 9

Multikine is One-of-a-kind

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: WASSERMAN R

Price: 25.00

Research Provided by a Third Party

Company: Cel-Sci Corporation

Industry: Medical - Biomedical and Genetics

Record: 22

02/11/2015

Company Report

Pages: 8

Continuing to enroll patients in Multikine trial

Provider: STONEGATE CAPITAL MARKETS

Analyst: TRANG D

Price: 25.00

Research Provided by a Third Party

Company: Cel-Sci Corporation

Industry: Medical - Biomedical and Genetics

Record: 23

01/08/2015

Company Report

Pages: 8

Arbitration date with former CRO set for May 2015.

Provider: STONEGATE CAPITAL MARKETS

Analyst: TRANG D

Price: 25.00

Research Provided by a Third Party

Company: Cel-Sci Corporation

Industry: Medical - Biomedical and Genetics

Record: 24

01/08/2015

Company Report

Pages: 8

Research Update: Arbitration date with former CRO set for May 2015

Provider: STONEGATE CAPITAL MARKETS

Analyst: TRANG D

Price: 25.00

Research Provided by a Third Party

Company: Cel-Sci Corporation

Industry: Medical - Biomedical and Genetics

Record: 25

09/08/2014

Company Report

Pages: 16

Initiation of Coverage: CVM: Unique cancer therapy looking to unlock potential

Provider: STONEGATE CAPITAL MARKETS

Analyst: TRANG D

Price: 50.00

Research Provided by a Third Party

Company: Cel-Sci Corporation

Industry: Medical - Biomedical and Genetics

Record: 26

12/09/2013

Company Report

Pages: 4

Dropping coverage due to termination of research services.

Provider: Taglich Brothers, Inc.

Analyst: NOBLE J

Price: 10.00

Research Provided by a Third Party

Company: Cel-Sci Corporation

Industry: Medical - Biomedical and Genetics

Record: 27

08/12/2013

Company Report

Pages: 18

Maintaining Speculative Buy rating and $0.70 (12-month) price target.

Provider: Taglich Brothers, Inc.

Analyst: NOBLE J

Price: 50.00

Research Provided by a Third Party

Company: Cel-Sci Corporation

Industry: Medical - Biomedical and Genetics

Record: 28

05/17/2013

Company Report

Pages: 18

Maintaining Speculative Buy rating and $0.70 (12-month) price target

Provider: Taglich Brothers, Inc.

Analyst: NOBLE J

Price: 50.00

Research Provided by a Third Party

Company: Cel-Sci Corporation

Industry: Medical - Biomedical and Genetics

Record: 29

02/19/2013

Company Report

Pages: 17

Initiating as Speculative Buy with a $0.70 (12-month) price target

Provider: Taglich Brothers, Inc.

Analyst: NOBLE J

Price: 50.00

Research Provided by a Third Party